TendieTensor TendieTensor
You’re browsing as
Guest
Free Preview
Sign in/sign up to unlock all features.

News  ›  GlobeNewswire Inc.

HUTCHMED Announces Positive Topline Results of Phase III Part of ESLIM-02 Trial of Sovleplenib for Warm Antibody Autoimmune Hemolytic Anemia in China

GlobeNewswire Inc. Logo GlobeNewswire Inc. By Hutchmed (China) Limited
HUTCHMED Announces Positive Topline Results of Phase III Part of ESLIM-02 Trial of Sovleplenib for Warm Antibody Autoimmune Hemolytic Anemia in China

HUTCHMED announced positive Phase III topline results for sovleplenib in treating warm antibody autoimmune hemolytic anemia (wAIHA) in China, meeting its primary endpoint of durable hemoglobin response rate. The company plans to submit a New Drug Application to China's NMPA in the first half of 2026. Phase II results showed a 43.8% response rate versus 0% for placebo in the first 8 weeks.

Insights
WMT   positive

Successful omnichannel strategy, competitive pricing, robust fulfillment network, loyal customer base, and 14% year-to-date stock performance


HCM   positive

The company achieved positive Phase III topline results meeting primary endpoints for sovleplenib in wAIHA treatment, demonstrating rapid and durable hemoglobin responses. This represents meaningful clinical progress toward regulatory approval and potential commercialization in China, with NDA submission planned for H1 2026.